Overview
Dr. Tanguy Seiwert is an oncologist in Baltimore, caring for patients with head and neck cancer. He serves as the director of the Head and Neck Cancer Oncology Disease Program and the co-director of the Bloomberg~Kimmel Institute for Immunotherapy at the Head and Neck Cancer Program at the Johns Hopkins School of Medicine. Dr. Seiwert earned his M.D. at Johannes Gutenberg Universität in Mainz, Germany. He completed his residency at the Duke University School of Medicine and performed a fellowship in hematology/oncology at the University of Chicago Medicine Mitchell Hospital-Hyde Park. Dr. Seiwert joined the Johns Hopkins faculty in 2019. Prior to joining Johns Hopkins, Dr. Seiwert was director of the Head and Neck Cancer Program at the University of Chicago. Dr. Seiwert’s research interests include immunologic and genomic profiling. He has given numerous invited talks on head and neck cancer both nationally and internationally. Dr. Seiwert served as chief editor for Frontiers in Head and Neck Cancer and as an editorial board member for the Journal of Clinical Oncology and Oral Oncology. He is a reviewer for multiple medical journals, including Lancet Oncology, Annals of Oncology and Clinical Cancer Research. He has been recognized by the American Association for Clinical Oncology for multiple Merit Awards and a Young Investigator Award. He was a member of the NCI Head and Neck Cancer Steering Committee, and is a member of the American Association for Clinical Oncology, the Society for Immunotherapy of Cancer, and the European Society of Clinical Oncology.
Dr. Seiwert is rated as an Experienced provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. His top areas of expertise are Glioma, Laryngeal Cancer, Tongue Cancer, Oral Squamous Cell Carcinoma, and Gastrostomy.
His clinical research consists of co-authoring 11 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
5759 Cedar Ln, Columbia, MD 21044
600 N Wolfe St, Blalock 266, Baltimore, MD 21287
5755 Cedar Ln, Columbia, MD 21044
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Skip Viragh Outpatient Cancer Center
Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Pancreaticoduodenectomy.
Inova Health Care Services
Sekwon Jang is a Hematologist Oncology specialist and an Oncologist in Falls Church, Virginia. Dr. Jang is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma (CTCL), and Squamous Cell Skin Carcinoma. Dr. Jang is currently accepting new patients.
Skin Care Specialty Physicians LLC
Amita Bagal is a Plastic Surgeon and an Otolaryngologist in Lutherville, Maryland. Dr. Bagal is rated as an Advanced provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. Her top areas of expertise are Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Ear Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Bagal is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- GliomaDr. Seiwert isDistinguished. Learn about Glioma.
- Advanced
- Acinic Cell Carcinoma of Salivary Glands
- Adenoid Cystic CarcinomaDr. Seiwert isAdvanced. Learn about Adenoid Cystic Carcinoma.
- Epithelial-Myoepithelial CarcinomaDr. Seiwert isAdvanced. Learn about Epithelial-Myoepithelial Carcinoma.
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Laryngeal CancerDr. Seiwert isAdvanced. Learn about Laryngeal Cancer.
- Nasopharyngeal CarcinomaDr. Seiwert isAdvanced. Learn about Nasopharyngeal Carcinoma.
- Experienced
- AgranulocytosisDr. Seiwert isExperienced. Learn about Agranulocytosis.
- Alveolar Soft Part SarcomaDr. Seiwert isExperienced. Learn about Alveolar Soft Part Sarcoma.
- Anaplastic Thyroid CancerDr. Seiwert isExperienced. Learn about Anaplastic Thyroid Cancer.
- Angiosarcoma of the ScalpDr. Seiwert isExperienced. Learn about Angiosarcoma of the Scalp.
- Bone TumorDr. Seiwert isExperienced. Learn about Bone Tumor.
- Chronic Familial NeutropeniaDr. Seiwert isExperienced. Learn about Chronic Familial Neutropenia.